Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.leukres.2009.03.037 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The role of antibody therapies in treating relapsed chronic lymphocytic leukemia: a review.
Expert Opin Biol Ther
November 2024
Department of Hematology, Medical University of Lodz, Lodz, Poland.
Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common types of leukemia in adult patients. The landscape of CLL therapy has changed in the last decades with the introduction of antibody-based therapies and novel targeted agents resulting in improved outcomes.
Areas Covered: This article describes the use of monoclonal antibodies, bispecific antibodies and antibody-drug conjugates in the treatment of relapsed and refractory CLL.
Toxicity Profile of eBAT, a Bispecific Ligand-Targeted Toxin Directed to EGFR and uPAR, in Mice and a Clinical Dog Model.
Toxins (Basel)
August 2024
Animal Cancer Care and Research Program, University of Minnesota, St. Paul, MN 55108, USA.
EGFR-targeted therapies are efficacious, but toxicity is common and can be severe. Urokinase type plasminogen activator receptor (uPAR)-targeted drugs are only emerging, so neither their efficacy nor toxicity is fully established. Recombinant eBAT was created by combining cytokines EGF and uPA on the same single-chain molecule with truncated toxin.
View Article and Find Full Text PDFAdvances in the treatment of adults with newly diagnosed B-cell acute lymphoblastic leukemia: the role of frontline immunotherapy-based regimens.
Leuk Lymphoma
October 2024
Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Blinatumomab and inotuzumab ozogamicin (INO) are both active in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and improve outcomes compared with conventional chemotherapy in this setting. Several prospective clinical trials have explored the use of these agents in adults with newly diagnosed B-cell ALL, with promising outcomes observed in younger and older adults and in both Philadelphia chromosome (Ph)-positive and Ph-negative ALL. These novel regimens result in high rates of deep measurable residual disease (MRD) negativity and may improve survival compared with chemotherapy-only approaches, allowing for less reliance on intensive chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT).
View Article and Find Full Text PDFNaked antibodies and antibody-drug conjugates: targeted therapy for childhood acute lymphoblastic leukemia.
Haematologica
June 2024
Princess Máxima Center for Pediatric Oncology, Utrecht; Pediatric Oncology, Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.
The treatment of childhood acute lymphoblastic leukemia (ALL) has reached overall survival rates exceeding 90%. The present and future challenges are to cure the remainder of patients still dying from disease, and to reduce morbidity and mortality in those who can be cured with standard-of-care chemotherapy by replacing toxic chemotherapy elements while retaining cure rates. With the novel therapeutic options introduced in the last years, including immunotherapies and targeted antibodies, the treatment of ALL is undergoing major changes.
View Article and Find Full Text PDFCombination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
Haematologica
September 2024
Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, TX.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!